Treat to target in gout

Area of Science:

• Rheumatology
• Clinical Medicine
• Evidence-Based Practice

Background:

• The treat-to-target (T2T) approach is established for various diseases.
• T2T has been proposed for rheumatic conditions including rheumatoid arthritis, spondyloarthritis, lupus, and gout.
• The level of evidence for T2T varies across conditions, with moderate to high evidence for hyperlipidemia.

Purpose of the Study:

• To evaluate the application and implications of the treat-to-target approach in gout management.
• To discuss the current evidence base for T2T in gout and contrast it with symptom-based approaches.
• To highlight the long-term consequences of not treating gout to target.

Main Methods:

• Review of existing literature and evidence for T2T strategies in rheumatic diseases.
• Analysis of proposed target serum urate levels for gout management.
• Comparison of T2T approach versus symptom-only management in gout.

Main Results:

• Long-term undertreatment of gout is associated with increased flares, tophi formation, and structural damage.
• These negative outcomes contribute to a diminished quality of life and increased mortality.
• Specific serum urate targets are proposed: <6 mg/dl for all gout patients, and <5 mg/dl for severe or tophaceous gout.

Conclusions:

• The T2T approach, while not fully evidenced for gout, shows promise in preventing long-term disease progression.
• A conservative, symptom-only approach may lead to worsening gout outcomes.
• Implementing T2T with defined serum urate targets is crucial for improving patient prognosis and quality of life in gout.